2no9: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,330,058 edits
No edit summary
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,330,058 edits
No edit summary
Line 1: Line 1:
[[Image:2no9.gif|left|200px]]
{{Seed}}
[[Image:2no9.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2no9|  PDB=2no9  |  SCENE=  }}  
{{STRUCTURE_2no9|  PDB=2no9  |  SCENE=  }}  


'''The structure of deoxycytidine kinase complexed with troxacitabine and ADP.'''
===The structure of deoxycytidine kinase complexed with troxacitabine and ADP.===




==Overview==
<!--  
L-nucleoside analogs represent an important class of small molecules for treating both viral infections and cancers. These pro-drugs achieve pharmacological activity only after enzyme-catalyzed conversion to their tri-phosphorylated forms. Herein, we report the crystal structures of human deoxycytidine kinase (dCK) in complex with the L-nucleosides (-)-beta-2',3'-dideoxy-3'-thiacytidine (3TC)--an approved anti-human immunodeficiency virus (HIV) agent--and troxacitabine (TRO)--an experimental anti-neoplastic agent. The first step in activating these agents is catalyzed by dCK. Our studies reveal how dCK, which normally catalyzes phosphorylation of the natural D-nucleosides, can efficiently phosphorylate substrates with non-physiologic chirality. The capability of dCK to phosphorylate both D- and L-nucleosides and nucleoside analogs derives from structural properties of both the enzyme and the substrates themselves. First, the nucleoside-binding site tolerates substrates with different chiral configurations by maintaining virtually all of the protein-ligand interactions responsible for productive substrate positioning. Second, the pseudo-symmetry of nucleosides and nucleoside analogs in combination with their conformational flexibility allows the L- and D-enantiomeric forms to adopt similar shapes when bound to the enzyme. This is the first analysis of the structural basis for activation of L-nucleoside analogs, providing further impetus for discovery and clinical development of new agents in this molecular class.
The line below this paragraph, {{ABSTRACT_PUBMED_17158155}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 17158155 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_17158155}}


==About this Structure==
==About this Structure==
Line 31: Line 35:
[[Category: L-dc]]
[[Category: L-dc]]
[[Category: Troxacitabine]]
[[Category: Troxacitabine]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May  4 09:41:57 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 05:12:22 2008''

Revision as of 02:12, 29 July 2008

File:2no9.png

Template:STRUCTURE 2no9

The structure of deoxycytidine kinase complexed with troxacitabine and ADP.

Template:ABSTRACT PUBMED 17158155

About this Structure

2NO9 is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

Structural basis for activation of the therapeutic L-nucleoside analogs 3TC and troxacitabine by human deoxycytidine kinase., Sabini E, Hazra S, Konrad M, Burley SK, Lavie A, Nucleic Acids Res. 2007;35(1):186-92. Epub 2006 Dec 7. PMID:17158155

Page seeded by OCA on Tue Jul 29 05:12:22 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "https://proteopedia.org/index.php?title=2no9&oldid=728477"